ArticleHistochemistry and cell biology2026
Vitamin D receptor suppresses pulmonary fibroblast activation by downregulating the TGF-β1/Smad signaling pathway.
Article in Histochemistry and cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
Abstract
The vitamin D receptor (VDR) has been implicated in anti-inflammatory and antifibrotic effects, but its role in regulating TGF-β1/Smad signaling and fibroblast activation in pulmonary fibrosis remains unclear. This study investigates the regulatory effects of VDR on TGF-β1/Smad signaling and its impact on fibrogenic responses in lung fibroblasts. MRC-5 cells were treated with L-lactate sodium to generate a fibrotic model, and VDR and TGF-β1 expression were manipulated using plasmids and siRNA. Fibroblast activation, TGF-β1/Smad signaling, and ECM remodeling were assessed using qRT-PCR, western blot, and immunofluorescence, while cell proliferation, migration, invasion, oxidative stress, and inflammation were also evaluated. Lactate stimulation increased α-SMA and collagen I/III expression, confirming fibroblast activation. VDR overexpression reduced fibrotic markers, downregulated ECM-degrading enzymes (MMP2, MMP9), and upregulated TIMP-1, while inhibiting migration, invasion, and reducing ROS and inflammatory cytokines (IL-6, IL-1β). In contrast, VDR knockdown enhanced fibrotic marker expression and fibroblast activity. Phosphorylation of Smad2/3 decreased with VDR overexpression and increased with knockdown. TGF-β1 overexpression elevated fibrotic markers and Smad signaling, while TGF-β1 knockdown reduced these markers and alleviated the activated phenotype. Exogenous TGF-β1 treatment reversed the antifibrotic effects of VDR overexpression, linking VDR to TGF-β1/Smad signaling. VDR suppresses fibroblast activation and fibrotic responses in lung fibroblasts by downregulating the TGF-β1/Smad signaling pathway, highlighting its potential as a therapeutic target for pulmonary fibrosis.
Indexed as
Identifiers
41784830What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.